Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

Algosun Global

Equity Capital Markets

German global clinical-stage biotech company and coronavirus vaccine developer CureVac set terms for $200M+ IPO (~13.3 million shares) at a valuation range of $16 per share or IPO valuation of ~$2.9B at top of the price range. Lead underwriters are BofA Securities, Jefferies and Credit Suisse. Globally 18M people had confirmed infection with COVID-19 virus and ~700K have died from COVID-19. in United States 4.7M COVID-19 cases and 150K deaths from COVID-19 have been confirmed with forecasted ~400K total deaths from COVID-19 by the end of 2020. Mr. Dietmar Hopp, managing director of Dievini Hopp Biotech Holding has agreed to purchase €100 million of common shares of CVAC at the initial public offering price per share in a private placement transaction. We estimate net proceeds from the offering to reach ~$213 million and forecast CVAC shares have ~200% upside potential to IPO valuation of ~$2.9B or IPO price $16 per share.

German global clinical-stage biotech company and coronavirus vaccine developer CureVac set terms for $200M+ IPO (~13.3 million shares) at a valuation range of $16 per share or IPO valuation of ~$2.9B at top of the price range. Lead underwriters are BofA Securities, Jefferies and Credit Suisse. Globally 18M people had confirmed infection with COVID-19 virus and ~700K have died from COVID-19. in United States 4.7M COVID-19 cases and 150K deaths from COVID-19 have been confirmed with forecasted ~400K total deaths from COVID-19 by the end of 2020. Mr. Dietmar Hopp, managing director of Dievini Hopp Biotech Holding has agreed to purchase €100 million of common shares of CVAC at the initial public offering price per share in a private placement transaction. We estimate net proceeds from the offering to reach ~$213 million and forecast CVAC shares have ~200% upside potential to IPO valuation of ~$2.9B or IPO price $16 per share.

CureVac IPO. Beating Rivals to Secure a COVID-19 Vaccine Based on MRNA Technology

United States

CureVac N.V. operates as a global clinical-stage biopharmaceutical company. The Company focuses on developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. CureVac serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CureVac NV (CVAC US)

CureVac IPO. Beating Rivals to Secure a COVID-19 Vaccine Based on MRNA Technology

German global clinical-stage biotech company and coronavirus vaccine developer CureVac set terms for $200M+ IPO (~13.3 million shares) at a...

Andrei Zakharov

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)